The European Medicines Agency said in a
statement that it was advising the use of the new drug, sold as Evusheld, in
people age 12 and over before they were exposed to COVID-19, to prevent future
infections.
It is now up to the EU’s executive arm, the
European Commission, to officially authorize the drug.
The U.S. Food and Drug Administration
cleared the medication in December for people with serious health problems or
allergies who can’t get adequate protection from vaccination. Britain
authorized the use of Evusheld last week.
“When the antibodies in Evusheld attach to
the spike protein, the virus cannot enter the cells to multiply and is unable
to cause COVID-19 infection,” the EMA said. The agency said it had assessed
data on the drug from more than 5,000 people and found Evusheld reduced the
risk of infection by 77%, with protection estimated to last at least six
months.
EMA said the drug’s side effects were
mostly mild, with some people reporting reactions at the injection point. The
agency noted that research was done before the emergence of the hugely infectious
omicron variant and said that it was evaluating data to determine if a
different dose might be needed.
Although antibody drugs have been a
standard treatment for treating COVID-19 infections for more than a year,
AstraZeneca’s is the first intended for long-term prevention against COVID-19
infection rather than as a short-term treatment.
People who could benefit from the antibody
drug include cancer patients, organ transplant recipients and individuals
taking immune-suppressing drugs for conditions like rheumatoid arthritis. -AP
0 comments:
Post a Comment